Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132652
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2005-08-18
Brief Title:
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine LdT vs Continued Lamivudine Treatment in Adults With Chronic Hepatitis B
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine LdT against continued lamivudine treatment Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients who continued on lamivudine alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None